Newsroom
23 press releases and 54 media coverage stories
BioProcess International: Prioritize Simplifying Processes Over Automating
BioProcess International
Automation is necessary for the future of CGT manufacturing to reduce contamination risk. However, as Jenny Stjernberg of ScaleReady highlights in this BioProcess International article, premature automation without simplifying processes can lead to longer timelines, increased risk, and financial strain.
Read the article : BioProcess International: Prioritize Simplifying Processes Over AutomatingShare: BioProcess International: Prioritize Simplifying Processes Over Automating
Pharma’s Almanac: What Conventional Industry Wisdom is Misguided, Outdated, or Wrong?
Pharma's Almanac
Industry experts, including Jenny Stjernberg, Ph.D., Commercial Director, EMEA, discuss which conventional industry wisdom they believe is misguided, outdated, or just plain wrong with Pharma's Almanac. Jenny discusses how many developers have too-literally retained the conventional wisdom that for cell-based therapies "process is product."
Read the article : Pharma’s Almanac: What Conventional Industry Wisdom is Misguided, Outdated, or Wrong?Share: Pharma’s Almanac: What Conventional Industry Wisdom is Misguided, Outdated, or Wrong?
Pharma’s Almanac: Leveraging Real-word Data in Cell and Gene Therapy
Pharma's Almanac
Cell therapies show remarkable potential in treating challenging lymphomas, as demonstrated by real-world data. But companies may run out of funds before reaching milestones due to factors like inefficient manufacturing, facility costs, and difficulties scaling processes. Alaina Schlinker, Ph.D., Senior Manager, Field Applications Support, ScaleReady, discusses how ScaleReady's platforms aim to help developers reach clinical milestones quickly and cost-effectively.
Read the article : Pharma’s Almanac: Leveraging Real-word Data in Cell and Gene TherapyShare: Pharma’s Almanac: Leveraging Real-word Data in Cell and Gene Therapy
Drug Discovery World: Advanced Therapies Europe: From bench to bedside and boardroom
Drug Discovery World
Drug Discovery World asked Advanced Therapies Europe attendees: What is most important to scale from discovery to commercialization of cell and gene therapies (CGTs)? ScaleReady’s Josh Ludwig answers.
Read the article : Drug Discovery World: Advanced Therapies Europe: From bench to bedside and boardroomShare: Drug Discovery World: Advanced Therapies Europe: From bench to bedside and boardroom
RegMedNet Interview: Preserving flexibility and the significance of cryopreservation in every step of the cell and gene therapy workflow
RegMedNet
In an exclusive interview with RegMedNet, Jenny Stjernberg discusses the crucial role of scalability in advancing groundbreaking therapies. Stjernberg emphasizes the importance of preserving flexibility while scaling up cell therapy manufacturing approaches.
Read the article : RegMedNet Interview: Preserving flexibility and the significance of cryopreservation in every step of the cell and gene therapy workflowShare: RegMedNet Interview: Preserving flexibility and the significance of cryopreservation in every step of the cell and gene therapy workflow
RegMedNet: Standardizing Cell Therapy Processes
RegMedNet
In this interview, Josh Ludwig talks about the importance of collaboration and standardization in developing and manufacturing cell therapies. Josh explains how standardizing processes across the industry can be achieved by…
Read the article : RegMedNet: Standardizing Cell Therapy ProcessesShare: RegMedNet: Standardizing Cell Therapy Processes
The Medicine Maker: Roundtable Discussion — Redefining Manufacturing
The Medicine Maker
Watch the roundtable discussion from Medicine Maker featuring experts from ScaleReady, Terumo Blood and Cell Technologies, Orgenesis, and BioBridge Global.
Read the article : The Medicine Maker: Roundtable Discussion — Redefining ManufacturingShare: The Medicine Maker: Roundtable Discussion — Redefining Manufacturing
Pharma’s Almanac: Artificial Intelligence (AI) Trends in Biopharma
Pharma's Almanac
In this edition of Pharma's Almanac, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss increased innovation and adoption of artificial intelligence (AI) and machine learning in biopharma.
Read the article : Pharma’s Almanac: Artificial Intelligence (AI) Trends in BiopharmaShare: Pharma’s Almanac: Artificial Intelligence (AI) Trends in Biopharma
Cell & Gene Therapy Insights: D More with Less Cell Culture in Immune Cell Therapies
Cell & Gene Therapy Insights
In this expert roundtable, David McCall, Senior Editor, BioInsights, speaks to Anastasiya Smith, Senior Director of R&D, CellReady; Josh Ludwig, Global Director, Commercial Operations, ScaleReady; and David Hermanson, Senior Manager of R&D Applications, Cell and Gene Therapy, Bio-Techne.
Read the article : Cell & Gene Therapy Insights: D More with Less Cell Culture in Immune Cell TherapiesShare: Cell & Gene Therapy Insights: D More with Less Cell Culture in Immune Cell Therapies
BioCentury: Cell and gene therapy must prioritize simplification, standardization before focusing on automation
BioCentury
Josh Ludwig, Global Director of Commercial Operations at ScaleReady, reviews how the industry is addressing the challenges that come with scaling up production to meet growth and demand and the…
Read the article : BioCentury: Cell and gene therapy must prioritize simplification, standardization before focusing on automationShare: BioCentury: Cell and gene therapy must prioritize simplification, standardization before focusing on automation
Phacilitate: Early Adoption and Partnerships – The Secret to Commercialization Success?
Phacilitate
Terumo’s Stuart Gibb, Ph.D., at Terumo Blood and Cell Technologies, is joined by Nisha C. Durand, PhD, at Mayo Clinic and Matthew M. Hewitt, B.A. Ph.D., Charles River.
Read the article : Phacilitate: Early Adoption and Partnerships – The Secret to Commercialization Success?Share: Phacilitate: Early Adoption and Partnerships – The Secret to Commercialization Success?
Bio-Techne Announces Investment in Wilson Wolf
PR Newswire
Bio-Techne Corporation announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million, triggering Bio-Techne's initial investment in the company, which…
Read the article : Bio-Techne Announces Investment in Wilson WolfShare: Bio-Techne Announces Investment in Wilson Wolf
